| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 1101- | CA, | Tras, | Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells |
| - | in-vitro, | BC, | NA |
| 4263- | CA, | Neuroprotective Effects of Carnosic Acid: Insight into Its Mechanisms of Action |
| - | Review, | AD, | NA |
| 1230- | CA, | Caff, | Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | Human, | NA, | NA |
| 5750- | CA, | Exploration of the anticancer properties of Caffeic Acid in malignant mesothelioma cells |
| - | in-vitro, | MM, | NA |
| 5747- | CA, | Caffeic Acid Enhances Anticancer Drug-induced Apoptosis in Acid-adapted HCT116 Colon Cancer Cells |
| - | in-vitro, | CRC, | NA |
| 5870- | CA, | Carnosic Acid Mediates Production of Reactive Oxygen Species to Regulate Mitogen‐Activated Protein Kinase Pathway Phosphorylation and Induce Apoptosis in Human Breast Cancer Cells |
| - | vitro+vivo, | BC, | T47D | - | in-vitro, | BC, | MCF-7 |
| 5874- | CA, | Carnosic Acid Mediates Production of Reactive Oxygen Species to Regulate Mitogen-Activated Protein Kinase Pathway Phosphorylation and Induce Apoptosis in Human Breast Cancer Cells |
| - | vitro+vivo, | BC, | T47D | - | in-vitro, | BC, | MCF10 |
| 5923- | CA, | RosA, | Rosemary as a Potential Source of Natural Antioxidants and Anticancer Agents: A Molecular Docking Study |
| - | Review, | Var, | NA |
| 5841- | CAP, | The red pepper’s spicy ingredient capsaicin activates AMPK in HepG2 cells through CaMKKβ |
| - | in-vitro, | HCC, | HepG2 |
| 5859- | CAP, | Are We Ready to Recommend Capsaicin for Disorders Other Than Neuropathic Pain? |
| - | Review, | Var, | NA |
| 5848- | CAP, | SRF, | Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HUH7 |
| 5846- | CAP, | Capsaicin Alters the Expression of Genetic and Epigenetic Molecules In Hepatocellular Carcinoma Cell |
| - | in-vitro, | HCC, | HepG2 |
| 1260- | CAP, | Capsaicin inhibits in vitro and in vivo angiogenesis |
| - | vitro+vivo, | NA, | NA |
| 2016- | CAP, | Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin) |
| 2018- | CAP, | MF, | Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2019- | CAP, | Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer |
| - | Review, | Var, | NA |
| 5768- | CAPE, | Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 5767- | CAPE, | Caffeic Acid Phenethyl Ester Is a Potential Therapeutic Agent for Oral Cancer |
| - | Review, | Oral, | NA |
| 5887- | CAR, | TV, | Antitumor Effects of Carvacrol and Thymol: A Systematic Review |
| - | Review, | Var, | NA |
| 5886- | CAR, | Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo |
| - | in-vivo, | GBM, | U87MG | - | in-vivo, | GBM, | U251 |
| 5885- | CAR, | Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HEK293 |
| 5882- | CAR, | Carvacrol Promotes Cell Cycle Arrest and Apoptosis through PI3K/AKT Signaling Pathway in MCF-7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 5905- | CAR, | HCQ, | Synergistic inhibition of metastatic melanoma by carvacrol and chloroquine: an in vitro and in silico investigation of apoptosis and molecular targets |
| - | in-vitro, | Melanoma, | NA |
| 5903- | CAR, | TV, | Combined Cytotoxic Effects of Carvacrol-Based Essential Oil Formulations |
| - | in-vitro, | BC, | MDA-MB-231 |
| 5893- | CAR, | TV, | Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management |
| - | Review, | Var, | NA |
| 5912- | CAR, | Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation migration and invasion |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HEK293 |
| - | in-vitro, | Kidney, | HK-2 |
| 3869- | Carno, | Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 5963- | CEL, | Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis |
| - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HepG2 |
| 5965- | CEL, | Cisplatin, | Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway |
| - | in-vitro, | OS, | MG63 |
| 5964- | CEL, | Celecoxib pathways: pharmacokinetics and pharmacodynamics |
| - | Review, | Var, | NA |
| 5954- | CEL, | The molecular mechanisms of celecoxib in tumor development |
| - | Review, | Var, | NA |
| 5939- | Cela, | Chemo, | Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells |
| - | in-vitro, | Melanoma, | U266 | - | in-vitro, | Melanoma, | RPMI-8226 |
| 5940- | Cela, | Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway |
| - | in-vivo, | Pca, | PC3 |
| 5943- | Cela, | Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases |
| - | Review, | Arthritis, | NA | - | Review, | IBD, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 5950- | Cela, | Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects |
| - | Review, | Var, | NA |
| 5951- | Cela, | Celastrol Suppresses Tumor Cell Growth through Targeting an AR-ERG-NF-κB Pathway in TMPRSS2/ERG Fusion Gene Expressing Prostate Cancer |
| - | vitro+vivo, | Pca, | NA |
| 2653- | Cela, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 6002- | CGA, | Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 6007- | CGA, | A Comprehensive View on the Impact of Chlorogenic Acids on Colorectal Cancer |
| - | Review, | CRC, | NA |
| 6009- | CGA, | Chlorogenic Acid: An In-Depth Review of Its Effectiveness in Cancer Treatment |
| - | Review, | Var, | NA |
| 6012- | CGA, | Chlorogenic Acid as a Potential Therapeutic Agent for Cholangiocarcinoma |
| - | in-vitro, | CCA, | HCC9810 |
| 954- | CGA, | Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 6085- | CHOC, | Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model |
| - | in-vivo, | PC, | NA |
| - | in-vivo, | NA, | NA |
| 2801- | CHr, | AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 2805- | CHr, | Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC) |
| - | in-vitro, | ESCC, | KYSE150 | - | in-vivo, | ESCC, | NA |
| 2780- | CHr, | Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review |
| - | Review, | Var, | NA |
| 2781- | CHr, | PBG, | Chrysin a promising anticancer agent: recent perspectives |
| - | Review, | Var, | NA |
| 2782- | CHr, | Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid